Commonly Targeted Antigens on B-Cell NHL with Corresponding mAbs
| Target antigen | Unconjugated mAb(s) | Generic name (trade name) | Corresponding radiolabeled mAb(s) | Generic name (trade name) | References |
|---|---|---|---|---|---|
| CD19 | Anti-B4 | — | — | — | 68 |
| HD37 | — | — | — | 45,69 | |
| CD21 | OKB7 | — | 131I-OKB7 | — | 14 |
| CD20 | B1 | Tositumomab | 131I-Tositumomab (Bexxar) | 16–18,30–38,42 | |
| 2B8 | Ibritumomab | IDEC-111In/90Y-2B8 | 111In/90Y-Ibritumomab tiuxetan (111In/Y90-Zevalin) | 2,3,23,26–29,43 | |
| 1F5 | — | 131I-1F5 | — | 18 | |
| C2B8 | Rituximab (Rituxan) | 131I-C2B8 | — | 70 | |
| CD22 | mLL2 | — | 131I-mLL2 | — | 15,19,20 |
| hLL2 | Epratuzumab (Lymphocide) | 131I-hLL2 | 131I-Epratuzumab | 19,24 | |
| 111In/90Y-hLL2 | 111In/90Y-Epratuzumab | 24,39 | |||
| 186Re-hLL2 | 186Re-Epratuzumab | 25 | |||
| HD6 | — | — | — | 45,69 | |
| CD37 | MB-1 | — | 131I-MB-1 | — | 11,12,18 |
| CD52 | Campath-1G | — | — | — | 67 |
| Campath-1H | Alemtuzumab | — | — | 67,71 | |
| HLA-DR | Lym-1 | 131I-Lym-1 | — | 5–10,21 | |
| 67Cu-Lym-1 | — | 21 | |||
| 90Y-Lym-1 | — | 22 | |||
| Hu1D10 | — | — | — | 72 |